Long Acting Injectable Medication Study for people with Schizophrenia
Protocol: SITE00000193
Full Title
Observational Study of LAIs In Schizophrenia (OASIS) (ALKS 9072-A403N)
Description
This study enrolls adults with schizophrenia who are currently in a treatment program for schizophrenia and your clinician is prescribing a Long
Acting Injectable (LAI) medication. The purpose of this study is to learn more about how patients do when they are on these medications.

Your health will be observed over time in order to collect information on the use of atypical Long Acting Injectable (LAI) antipsychotics in people with schizophrenia. We will collect this data about you for about 1 year. Being in the study won't change the usual routine care that you get from your provider. You will still go in for all the regular visits to your provider that you would if you were not in this study. Study takes place at ECMC.
Compensation: No
Eligibility
Adults ages 18+.
Diagnosis of schizophrenia.
Have just started treatment with one of four atypical Long Acting Injectable (LAI) medications (ABILIFY MAINTENA, ARISTADA, INVEGA SUSTENNA or RISPERDAL CONSTA)
Age Group: Adults
Principal Investigator: BISWARUP GHOSH
ClinicalTrials.gov: Open Study
Contact(s)
SEVIE KANDEFER
sk293@buffalo.edu
+1 716-898-4038
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact ctsiresearch@buffalo.edu.